Sino-US biotech company Phanes Therapeutics Inc. has announced that it has received another Fast Track designation from the US Food and Drug Administration (FDA) for its bispecific antibody (bsAb) PT217. This designation is specifically for the treatment of patients with metastatic de novo or treatment-emergent neuroendocrine prostate cancer (NEPC). Earlier this year, PT217 was also awarded fast-track status by the FDA for extensive-stage small cell lung cancer (ES-SCLC) with disease progression following platinum chemotherapy with or without a checkpoint inhibitor.
PT217: A Promising BsAb Targeting DLL3 and CD47
PT217 is an in-house developed bispecific antibody that targets DLL3 and CD47, and is being developed to treat multiple solid tumors. Both its SCLC and neuroendocrine carcinoma (NEC) indications have been awarded orphan drug designations (ODDs) in the US. This recognition underscores the potential impact of PT217 in addressing rare and serious diseases with unmet medical needs.
Collaboration with Roche on PT217
Phanes has previously enlisted the support of Roche to study PT217 in combination with atezolizumab, the Swiss giant’s anti-PD-L1 therapy. This collaboration aims to explore the potential synergistic effects of combining PT217 with immunotherapy, potentially enhancing the treatment options for patients with certain types of cancer.-Fineline Info & Tech
